Talphera (TLPH) Shares Outstanding (2010 - 2026)
Talphera (TLPH) posted Shares Outstanding (Entity) of $75.5 million for Q2 2026, up 8.17% on a QoQ basis from $69.8 million in Q1 2026, and up 118.73% year-over-year from $34.5 million in Q2 2025.
Analysis
Talphera (TLPH) Shares Outstanding (2010 - 2026) Analysis & Trends
Talphera has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $75.5 million in Q2 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 118.73% year-over-year to $75.5 million in Q2 2026; TTM through Jun 2026 was $75.5 million, a 118.73% increase from a year earlier, with the FY2025 full-year figure at $49.3 million, up 90.86% from the prior year.
- Shares Outstanding (Entity) was $75.5 million for Q2 2026 at Talphera, up from $69.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $75.5 million in Q2 2026, with the low at $7.4 million in Q1 2022.
- Average Shares Outstanding (Entity) over 5 years is $27.2 million, with a median of $25.3 million recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) climbed 6.25% in 2025, then surged 165.8% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $8.2 million in 2022, then surged by 105.64% to $17.0 million in 2023, then soared by 52.46% to $25.8 million in 2024, then surged by 90.86% to $49.3 million in 2025, then jumped by 53.11% to $75.5 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $75.5 million (Q2 2026), $69.8 million (Q1 2026), and $49.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 180.02 Bn | 176.84 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 131.54 Bn | 123.69 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.96 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 60.23 Bn | 55.04 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 53.85 Bn | 48.72 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.13 Bn | 29.82 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.88 Bn | 30.59 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | 720.78 Mn |
| 10 | Talphera | 93.28 Mn | 93.28 Mn | - | 75.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.53 Mn |
| Mar 31, 2026 | 69.82 Mn |
| Dec 31, 2025 | 42.41 Mn |
| Sep 30, 2025 | 41.45 Mn |
| Jun 30, 2025 | 34.53 Mn |
| Mar 31, 2025 | 26.27 Mn |
| Dec 31, 2024 | 25.85 Mn |
| Sep 30, 2024 | 26.21 Mn |
| Jun 30, 2024 | 26.20 Mn |
| Mar 31, 2024 | 24.72 Mn |
| Dec 31, 2023 | 14.26 Mn |
| Sep 30, 2023 | 16.76 Mn |
| Jun 30, 2023 | 10.92 Mn |
| Mar 31, 2023 | 10.89 Mn |
| Dec 31, 2022 | 7.39 Mn |
| Sep 30, 2022 | 7.38 Mn |
| Jun 30, 2022 | 7.36 Mn |
| Mar 31, 2022 | 7.28 Mn |
| Dec 31, 2021 | 5.99 Mn |
| Sep 30, 2021 | 5.96 Mn |